1.10
                                            
            Sutro Biopharma Inc stock is traded at $1.10, with a volume of 908.41K.
            It is down -1.79% in the last 24 hours and up +21.08% over the past month.
            Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
        
        See More
    Previous Close:
              $1.12
            Open:
              $1.12
            24h Volume:
                908.41K
            Relative Volume:
              1.10
            Market Cap:
                $93.25M
            Revenue:
              $153.73M
            Net Income/Loss:
              $-106.79M
            P/E Ratio:
              -0.618
            EPS:
                -1.78
            Net Cash Flow:
                $-115.93M
            1W Performance:
              -5.17%
            1M Performance:
              +21.08%
            6M Performance:
                +0.00%
            1Y Performance:
              -69.01%
            Sutro Biopharma Inc Stock (STRO) Company Profile
Name
                  
                      Sutro Biopharma Inc
                    
                Sector
                  Industry
                  Phone
                  
                      650-392-8412
                    
                Address
                  
                      111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
                    
                Compare STRO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS | 
|---|---|---|---|---|---|---|
| 
                         
                          
                                STRO
                            
                             
                        Sutro Biopharma Inc 
                           | 
                    1.10 | 94.95M | 153.73M | -106.79M | -115.93M | -1.78 | 
| 
                         
                          
                                VRTX
                            
                             
                        Vertex Pharmaceuticals Inc 
                           | 
                    426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 | 
| 
                         
                          
                                REGN
                            
                             
                        Regeneron Pharmaceuticals Inc 
                           | 
                    642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 | 
| 
                         
                          
                                ALNY
                            
                             
                        Alnylam Pharmaceuticals Inc 
                           | 
                    434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 | 
| 
                         
                          
                                ARGX
                            
                             
                        Argen X Se Adr 
                           | 
                    826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 | 
| 
                         
                          
                                INSM
                            
                             
                        Insmed Inc 
                           | 
                    186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 | 
Sutro Biopharma Inc Stock (STRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change | 
|---|---|---|---|
| Jun-16-25 | Upgrade | Piper Sandler | Neutral → Overweight | 
| Mar-17-25 | Downgrade | H.C. Wainwright | Buy → Neutral | 
| Mar-14-25 | Downgrade | BofA Securities | Buy → Underperform | 
| Mar-14-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform | 
| Mar-14-25 | Downgrade | Wedbush | Outperform → Neutral | 
| May-08-24 | Initiated | BofA Securities | Buy | 
| Nov-09-23 | Initiated | Deutsche Bank | Buy | 
| Oct-06-23 | Initiated | Oppenheimer | Outperform | 
| Mar-21-23 | Downgrade | Wells Fargo | Overweight → Equal Weight | 
| Aug-18-22 | Resumed | Wells Fargo | Overweight | 
| Jun-18-21 | Initiated | H.C. Wainwright | Buy | 
| Dec-03-20 | Initiated | Stifel | Buy | 
| Sep-02-20 | Initiated | Jefferies | Buy | 
| Jul-16-20 | Initiated | Wells Fargo | Overweight | 
| Jan-13-20 | Initiated | SunTrust | Buy | 
| Oct-07-19 | Initiated | BTIG Research | Buy | 
| Jul-18-19 | Initiated | Deutsche Bank | Buy | 
| Apr-29-19 | Initiated | H.C. Wainwright | Buy | 
| Oct-22-18 | Initiated | JMP Securities | Mkt Outperform | 
| Oct-22-18 | Initiated | Piper Jaffray | Overweight | 
| Oct-22-18 | Initiated | Wedbush | Outperform | 
                    View All
                    
                  
                Sutro Biopharma Inc Stock (STRO) Latest News
Statistical indicators supporting Sutro Biopharma Inc.’s strengthBond Market & AI Powered Market Trend Analysis - newser.com
Can technical indicators confirm Sutro Biopharma Inc.’s reversalJuly 2025 Drop Watch & Daily Profit Maximizing Trade Tips - newser.com
Sutro Biopharma Announces Participation at the 16th Annual World ADC Conference - The Manila Times
Sutro Biopharma, Inc. to Present Innovative Preclinical Data at World ADC Conference 2025 - Quiver Quantitative
Sutro (NASDAQ: STRO) to present preclinical data on dual-payload ADCs at World ADC - Stock Titan
What earnings margins imply for Sutro Biopharma Inc. (S09) stock2025 Valuation Update & Reliable Volume Spike Trade Alerts - newser.com
What candlestick patterns are forming on Sutro Biopharma Inc.Jobs Report & High Return Trade Guides - newser.com
Analyzing Sutro Biopharma Inc. with risk reward ratio chartsMarket Performance Summary & Long-Term Capital Growth Strategies - newser.com
Can Sutro Biopharma Inc. recover in the next quarterGap Down & Comprehensive Market Scan Insights - newser.com
Is it too late to sell Sutro Biopharma Inc.Weekly Trading Summary & Real-Time Volume Analysis - newser.com
Published on: 2025-11-02 22:36:42 - newser.com
Is Sutro Biopharma Inc. stock a safe haven assetDollar Strength & Daily Profit Focused Screening - newser.com
Is Sutro Biopharma Inc. stock a buy on dipsDividend Hike & AI Enhanced Trade Execution Alerts - newser.com
Can Sutro Biopharma Inc. (S09) stock deliver strong annual returnsWeekly Trade Review & High Conviction Buy Zone Alerts - newser.com
Applying Wyckoff theory to Sutro Biopharma Inc. stockDividend Hike & Smart Money Movement Alerts - newser.com
Published on: 2025-11-01 09:13:17 - newser.com
Volatility clustering patterns for Sutro Biopharma Inc.Index Update & Long-Term Growth Plans - newser.com
How to monitor Sutro Biopharma Inc. with trend dashboards2025 Valuation Update & Precise Buy Zone Tips - newser.com
How buybacks impact Sutro Biopharma Inc. stock valuePortfolio Update Report & Technical Confirmation Alerts - newser.com
Can Sutro Biopharma Inc. stock sustain revenue growthMarket Performance Recap & Smart Swing Trading Alerts - newser.com
Does Sutro Biopharma Inc. show high probability of rebound2025 Trade Ideas & Reliable Intraday Trade Alerts - newser.com
Identifying reversal signals in Sutro Biopharma Inc.Market Performance Recap & Real-Time Sentiment Analysis - newser.com
Why Sutro Biopharma Inc. stock is considered a top pick2025 Earnings Surprises & Technical Pattern Recognition Alerts - newser.com
Insider Sell: Why Sutro Biopharma Inc. stock is recommended by analystsJobs Report & Advanced Technical Analysis Signals - fcp.pa.gov.br
Sutro Biopharma Inc Stock (STRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
        Open in Yahoo
        |
        Open in Google
            |
            Open in Finviz
        |
        Open in MarketWatch
            |
            Open in EDGAR    
        |
        Open in Reuters
    
    
                Cap:
                 
                  | 
                Volume (24h):